OncLive® On Air S13 Ep38: Guideline Updates and Trial Data Solidify the Role of HER2/MET IHC Testing in NSCLC: With Martin F. Dietrich, MD, PhD
Aug 4, 2025
In this discussion, Dr. Martin F. Dietrich, a medical oncologist and assistant professor, dives into the significance of HER2 and MET immunohistochemistry testing for non-small cell lung cancer patients. He outlines the rationale for testing and the challenges oncologists face in implementing these guidelines. The conversation highlights the importance of retesting as patients progress, the potential of novel therapies, and the need for standardized workflows to improve patient outcomes in oncology.
AI Snips
Chapters
Transcript
Episode notes
HER2 And MET Added To IHC Panel
- HER2 and MET IHC testing joined PD-L1 in NCCN Category 2A recommendations.
- These surface markers open second-line targeted options via antibody‑drug conjugates.
Different Forms Of The Same Biomarker Matter
- HER2 and MET can appear as mutations, amplifications, or protein overexpression with different treatment implications.
- Combine DNA/RNA NGS with protein IHC to capture this multi-layered biomarker landscape.
MET Exon 14 Often Differs From Overexpression
- MET exon 14 skipping mutations do not reliably correlate with MET protein overexpression.
- Test exon 14, amplifications, and IHC separately to identify distinct patient groups.